HEMAY

Founded in 2002, Hemay is a pharmaceutical company dedicated to independent research and industrialization of innovative global drugs. The company focuses on unmet clinical needs as its research and development direction, with the development goal of "based in China and targeting the world", actively carrying out global projects, patents, and industrial layout. The company has established multiple subsidiaries, covering various functional sectors from research and development to production. Meimei Pharmaceutical has always taken "developing more effective, safer, and more economical new drugs for patients" as its mission, adhering to the attitude of "being responsible for patients", and actively building a world-class value drug research and production base through team collaboration and scientific innovation. The company's research and development does not blindly pursue new targets or hot tracks. It adheres to its own research and development platform and core technology as the basis, focusing on creating products with excellent clinical value. The company's research and development pipeline covers fields such as autoimmune diseases and tumors, and multiple indications are currently in the NDA or critical clinical trial stage. The project has received recognition and support from various levels of departments and research institutions multiple times, and has independently undertaken three major national scientific and technological projects for "major new drug creation".